26 completed, 11 recruiting, 5 active not recruiting, 4 withdrawn. 52 Phase 1, 21 Phase 2.
Follow Alcohol Use Disorder: new trials by email Literature Review of Alcohol Use Disorder trials Research Report on Alcohol Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Environment and Alcohol: A Pilot Study Evaluate the effects of Environmental Enrichment (EE) on alcohol consumption - Alcohol Use Disorder | Phase 1 | Recruiting | National Institute on Drug Abuse (NIDA) | 44 | 2026-11-19 | 2026-11-16 |
| Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients Sodium Acetate, Placebo - Alcohol Withdrawal, Alcohol Abstinence | Phase 1 / Phase 2 | Not yet recruiting | University of Colorado, Denver | 75 | 2026-11-01 | 2026-10-30 |
| Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) Semaglutide 1.0 mg - Alcohol Use Disorder, Weight Loss | Phase 1 | Active not recruiting | Yale University | 4 | 2026-03-26 | 2026-09-10 |
| Study of NTX-2001 on Alcohol Consumption in Alcohol Use Disorder NTX-2001, Placebo - Alcohol Use Disorder | Phase 1 | Recruiting | Newleos Therapeutics, Inc. | 50 | 2026-03-20 | 2026-04-09 |
| Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) Intravenous Ethanol, 18F-PF-06445974 - Alcohol Use Disorder | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 30 | 2025-12-11 | 2026-11-02 |
| The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration Oral disulfiram - Alcohol Use Disorder, Retinal Dystrophies | Phase 1 | Recruiting | University of Rochester | 15 | 2025-05-19 | 2026-09-16 |
| A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects CMND-100 - Alcohol Use Disorder | Phase 1 / Phase 2 | Recruiting | Clearmind Medicine Inc. | 84 | 2025-04-30 | 2026-03-31 |
| PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder 18F-PF-06445974, Oxazepam - Alcohol Use Disorder | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 30 | 2025-03-20 | 2026-10-27 |
| Intranasal Insulin for Treatment of Alcohol Use Disorder Regular Human Insulin then Placebo, Placebo then Regular Human Insulin - Alcohol Use Disorder | Phase 1 / Phase 2 | Recruiting | Brown University | 40 | 2025-02-25 | 2026-09-30 |
| PT150 Drug for Use in Alcohol Use Disorder alcohol, Stress-Induction, PT150 - Alcohol Use Disorder | Phase 1 | Recruiting | Pop Test Oncology LLC | 34 | 2025-02-01 | 2026-09-16 |
| Ketamine for Combined Depression and Alcohol Use Disorder Ketamine Hydrochloride, Midazolam Hydrochloride - Depression, Alcohol Use Disorder | Phase 1 / Phase 2 | Recruiting | University Hospital of North Norway | 34 | 2025-01-20 | 2026-06-23 |
| Enhancing the Effects of Alcohol Treatment With L-Carnitine L-carnitine - Alcohol Use Disorder | Phase 1 | Completed | Brown University | 24 | 2024-09-27 | 2025-06-15 |
| Treating Stress and Anxiety in Individuals With Alcohol Use Disorder (AUD) active heat, Active c tactile fiber stimulation, sham heat - Anxiety Disorders, Alcohol Use Disorder | Phase 1 | Unknown | Soovu Labs Inc. | 36 | 2024-07-15 | 2024-01-25 |
| Apremilast for Alcohol Use Disorder Treatment in Women and Men Apremilast - Alcohol Use Disorder | Phase 1 | Active not recruiting | Yale University | 10 | 2024-05-08 | 2026-02-03 |
| A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Prazosin + cyproheptadine, KT110 - Alcohol Use Disorder | Phase 1 | Completed | Kinnov Therapeutics | 12 | 2024-04-23 | 2025-03-13 |
| rTMS in Older Adults With MCI and AUD Active, Open Label iTBS-rTMS - Alcohol Use Disorder, Mild Cognitive Impairment | Phase 1 | Active not recruiting | Medical University of South Carolina | 35 | 2023-11-01 | 2026-09-17 |
| Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder Brexanolone - PTSD, Alcohol Use Disorder | Phase 1 | Active not recruiting | Yale University | 25 | 2023-08-01 | 2025-10-14 |
| Spironolactone in Alcohol Use Disorder (SAUD) Placebo, Spironolactone - Alcohol Use Disorder | Phase 1 | Recruiting | National Institute on Drug Abuse (NIDA) | 20 | 2023-07-13 | 2026-11-09 |
| Phase 1b Study of DCR-AUD in Healthy Volunteers DCR-AUD, Placebo - Alcohol Use Disorder | Phase 1 | Completed | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 16 | 2023-01-29 | 2026-01-14 |
| Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease Intestinal Microbiota Transplant (IMT) Capsules, Placebo Capsules - Liver Disease; Alcohol-Related, Cirrhosis | Phase 1 / Phase 2 | Active not recruiting | Virginia Commonwealth University | 80 | 2022-11-21 | 2026-08-24 |
Showing 20 of 52. Sign in to see all of them.
Alcoholism (52) · Alcohol Drinking (6) · Anxiety Disorders (4) · Stress Disorders, Post-Traumatic (3) · Alcohol-Related Disorders (2) · Depressive Disorder, Major (2) · Alcohol Abstinence (1) · Behavior, Addictive (1) · Cognition Disorders (1) · Cognitive Dysfunction (1) · Depression (1) · Emergencies (1) · Fibrosis (1) · Inflammation (1) · Liver Diseases (1)
Chemically-Induced Disorders (52) · Mental Disorders (52) · Substance-Related Disorders (51) · Alcohol-Related Disorders (50) · Behavior (10) · Drinking Behavior (7) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Stress Disorders, Traumatic (3) · Trauma and Stressor Related Disorders (3) · Behavioral Symptoms (2) · Depressive Disorder (2) · Disease Attributes (2) · Mood Disorders (2) · Neurocognitive Disorders (2)
Ethanol (6) · Pioglitazone (3) · Sugars (3) · Cannabidiol (2) · Ketamine (2) · (11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta(a)phenanthren-3-one (1) · Capsules (1) · Carnitine (1) · Cyproheptadine (1) · Disulfiram (1) · Doxazosin (1) · Duloxetine Hydrochloride (1) · Economics (1) · Exenatide (1) · Fecal Microbiota Transplantation (1)
Yale University (5) · Brown University (4) · Medical University of South Carolina (4) · The University of Texas Health Science Center, Houston (4) · Boston Medical Center (3) · National Institute on Drug Abuse (NIDA) (3) · NYU Langone Health (2) · National Institute of Mental Health (NIMH) (2) · University of California, Los Angeles (2) · VA Office of Research and Development (2) · Clearmind Medicine Inc. (1) · Craig Rush (1) · Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) · Icahn School of Medicine at Mount Sinai (1) · Ihsan M Salloum, MD, MPH (1)
United States (45) · France (1) · Israel (1) · Norway (1) · United Kingdom (1)
Eric Devine, PhD (3) · Lorenzo Leggio, M.D. (3) · Jin H Yoon, PhD (2) · Robert B Innis, M.D. (2) · Andreas W Blomkvist, M.D. (1) · Carolina L Haass-Koffler, PHARMD, PHD (1) · Charles Marmar, MD (1) · Craig Rush, PhD (1) · E. Sherwood Brown, MD, PhD, MBA (1) · Elizabeth Ralevski, PhD (1) · Ellen Burnham, MD (1) · Ethan Cowan, MD (1) · Gihyun Yoon, MD (1) · Ihsan Salloum, MD (1)
PMID 31535696, PMID 39472130, PMID 39719161, PMID 40492610, PMID 40584152, PMID 40795937, PMID 42258258
U54AA027989 (2), 2016 (1), 2023 (1), K01AA026005 (1), K01AA026874 (1), P50AA010761 (1), P50DA009262 (1), R01AA024933 (1), R01AA026255 (1), R01AA026514 (1), R01AA027236 (1), R01AA029398 (1), R01AA030774 (1), R21AA024917 (1), R21AA026389 (1)